FabH mutations confer resistance to fabf-directed antibiotics in Staphylococcus Aureus

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 849-858

  Parsons, Joshua B ^a   Yao, Jiangwei ^a   Frank, Matthew W ^a   Rock, Charles O ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FATTY ACID BINDING PROTEIN 2; PLATENCIN; PLATENSIMYCIN; THIOLACTOMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; FATTY ACID SYNTHASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; ENZYME ACTIVITY; MISSENSE MUTATION; NONHUMAN; OPERON; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; FATTY ACID SYNTHASE, TYPE II; MUTATION; MUTATION, MISSENSE; STAPHYLOCOCCUS AUREUS;

EID: 84921823596     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04179-14     Document Type: Article

References (54)

1. Parsons JB, Rock CO. 2011. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr Opin Microbiol 14:544-549. http: //dx.doi.org/10.1016/j.mib.2011.07.029.
2. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83-86. http://dx.doi.org/10.1038 /nature07772.
3. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2010. Brinster et al. reply. Nature 463:E4. http://dx.doi.org/10.1038/nature08668.
4. Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A. 2010. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463:E3. http://dx.doi.org/10.1038/nature08667.
5. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci U S A 108: 15378-15383. http://dx.doi.org/10.1073/pnas.1109208108.
6. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang C, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441:358-361. http://dx.doi.org/10.1038/nature04784.
7. Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, Diez MT, Vicente F, Gonzalez I, Salazar O, Pelaez F, Cummings R, Ha S, Wang J, Singh SB. 2007. Isolation and structure of platencin: a FabH and FabF dual inhibitor with potent broad-spectrum antibiotic activity. Angew Chem Int Ed Engl 46:4684-4688. http://dx.doi.org/10.1002/anie .200701058.
8. Liu X, Fortin PD, Walsh CT. 2008. Andrimid producers encode an acetyl-CoA carboxyltransferase subunit resistant to the action of the antibiotic. Proc Natl Acad Sci U S A 105:13321-13326. http://dx.doi.org/10 .1073/pnas.0806873105.
9. Miyakawa S, Suzuki K, Noto T, Harada Y, Okazaki H. 1982. Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. J Antibiot (Tokyo) 35:411-419.
10. Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, Schmid MB, Thalakada R, Yethon J, Pauls HW. 2012. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor Antimicrob. Agents Chemother 56:5865-5874. http: //dx.doi.org/10.1128/AAC.01411-12.
11. Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher K, Morrissey I, Soulama-Mouze C. 2011. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother 55:4692-4697. http://dx.doi.org /10.1128/AAC.01248-10.
12. Parsons JB, Frank MW, Rosch JW, Rock CO. 2013. Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob Agents Chemother 57:5729-5732. http://dx.doi.org/10.1128/AAC.01038-13.
13. Kaplan N, Garner C, Hafkin B. 2013. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur J Pharm Sci 50:440 - 446. http://dx.doi.org/10.1016/j.ejps .2013.08.019.
14. Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec G, Oliveira C, Desroy N, Raymond C, Peltier L, Moreau F, Escaich S, Vongsouthi V, Floquet S, Drocourt E, Walton A, Prouvensier L, Saccomani M, Durant L, Genevard JM, Sam-Sambo V, Soulama-Mouze C. 2012. From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria. J Med Chem 55: 9914-9928. http://dx.doi.org/10.1021/jm301113w.
15. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang C, Kodali S, Galgoci A, Painter R, Brown-Driver V, Yamamoto R, Silver LL, Zheng Y, Ventura JI, Sigmund J, Ha S, Basilio A, Vicente F, Tormo JR, Pelaez F, Youngman P, Cully D, Barrett JF, Schmatz D, Singh SB, Wang J. 2006. Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother 50:519-526. http://dx.doi.org/10.1128/AAC.50.2 .519-526.2006.
16. Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, Gonzalez I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully DF, Singh SB. 2007. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci U S A 104:7612-7616. http://dx.doi.org/10.1073/pnas .0700746104.
17. D'Agnolo G, Rosenfeld IS, Awaya J, Omura S, Vagelos PR. 1973. Inhibition of fatty acid biosynthesis by the antibiotic cerulenin. Specific inactivation of β-ketoacyl-acyl carrier protein synthetase. Biochim Biophys Acta 326:155-166.
18. Hayashi T, Yamamoto O, Sasaki H, Kawaguchi A, Okazaki H. 1983. Mechanism of action of the antibiotic thiolactomycin inhibition of fatty acid synthesis of Escherichia coli. Biochem Biophys Res Commun 115: 1108-1113. http://dx.doi.org/10.1016/S0006-291X(83)80050-3.
19. Price AC, Choi KH, Heath RJ, Li Z, Rock CO, White SW. 2001. Inhibition of β-ketoacyl-[acyl carrier protein] synthases by thiolactomycin and cerulenin: structure and mechanism. J Biol Chem 276:6551-6559. http://dx.doi.org/10.1074/jbc.M007101200.
20. Allahverdiyev AM, Bagirova M, Abamor ES, Ates SC, Koc RC, Miralo-glu M, Elcicek S, Yaman S, Unal G. 2013. The use of platensimycin and platencin to fight antibiotic resistance. Infect Drug Resist 6:99-114. http: //dx.doi.org/10.2147/IDR.S25076.
21. Martens E, Demain AL. 2011. Platensimycin and platencin: promising antibiotics for future application in human medicine. J Antibiot (Tokyo) 64:705-710. http://dx.doi.org/10.1038/ja.2011.80.
22. Machutta CA, Bommineni GR, Luckner SR, Kapilashrami K, Ruzsicska B, Simmerling C, Kisker C, Tonge PJ. 2010. Slow onset inhibition of bacterial β-ketoacyl-acyl carrier protein synthases by thiolactomycin. J Biol Chem 285:6161-6169. http://dx.doi.org/10.1074/jbc.M109.077909.
23. Wright GD. 2003. Mechanisms of resistance to antibiotics. Curr Opin Chem Biol 7:563-569. http://dx.doi.org/10.1016/j.cbpa.2003.08.004.
24. Schujman GE, Choi K-H, Altabe S, Rock CO, de Mendoza D. 2001. Response of Bacillus subtilis to cerulenin and the acquisition of resistance. J Bacteriol 183:3032-3040. http://dx.doi.org/10.1128/JB.183.10.3032-3040 .2001.
25. Peterson RM, Huang T, Rudolf JD, Smanski MJ, Shen B. 2014. Mechanisms of self-resistance in the platensimycin- and platencin-producing Streptomyces platensis MA7327 and MA7339 strains. Chem Biol 21:389-397. http://dx.doi.org/10.1016/j.chembiol.2014.01.005.
26. Furukawa H, Tsay J-T, Jackowski S, Takamura Y, Rock CO. 1993. Thiolactomycin resistance in Escherichia coli is associated with the multidrug resistance efflux pump encoded by emrAB. J Bacteriol 175:3723-3729.
27. Jackowski S, Zhang Y-M, Price AC, White SW, Rock CO. 2002. A missense mutation in the fabB (β-ketoacyl-acyl carrier protein synthase I) gene confers thiolactomycin resistance to Escherichia coli. Antimicrob Agents Chemother 46:1246-1252. http://dx.doi.org/10.1128/AAC.46.5 .1246-1252.2002.
28. Tsay J-T, Rock CO, Jackowski S. 1992. Overproduction of β-ketoacylacyl carrier protein synthase I imparts thiolactomycin resistance to Escherichia coli K-12. J Bacteriol 174:508-513.
29. Wang H, Claveau D, Vaillancourt JP, Roemer T, Meredith TC. 2011. High-frequency transposition for determining antibacterial mode of action. Nat Chem Biol 7:720-729. http://dx.doi.org/10.1038/nchembio.643.
30. Heath RJ, Rock CO. 1996. Inhibition of β-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. J Biol Chem 271:10996-11000. http://dx.doi.org/10.1074/jbc.271.18.10996.
31. Jiang Y, Morgan-Kiss RM, Campbell JW, Chan CH, Cronan JE. 2010. Expression of Vibrio harveyi acyl-ACP synthetase allows efficient entry of exogenous fatty acids into the Escherichia coli fatty acid and lipid A synthetic pathways. Biochemistry 49:718-726. http://dx.doi.org/10 .1021/bi901890a.
32. McAllister KA, Peery RB, Meier TI, Fischl AS, Zhao G. 2000. Biochemical and molecular analyses of the Streptococcus pneumoniae acyl carrier protein synthase, an enzyme essential for fatty acid biosynthesis. J Biol Chem 275:30864-30872. http://dx.doi.org/10.1074/jbc.M004475200.
33. Yao J, Maxwell JB, Rock CO. 2013. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J Biol Chem 288:36261-36271. http://dx.doi.org/10 .1074/jbc.M113.512905.
34. Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO. 2013. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother 57:2182-2190. http://dx .doi.org/10.1128/AAC.02307-12.
35. Theis T, Skurray RA, Brown MH. 2007. Identification of suitable internal controls to study expression of a Staphylococcus aureus multidrug resistance system by quantitative real-time PCR. J Microbiol Methods 70:355-362. http://dx.doi.org/10.1016/j.mimet.2007.05.011.
36. Winer J, Jung CK, Shackel I, Williams PM. 1999. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41-49. http://dx.doi.org/10.1006/abio.1999.4085.
37. Vance DE, Goldberg I, Mitsuhashi O, Bloch K, Omura S, Nomura S. 1972. Inhibition of fatty acid synthetases by the antibiotic cerulenin. Biochem Biophys Res Commun 48:649-656. http://dx.doi.org/10.1016 /0006-291X(72)90397-X.
38. He X, Reynolds KA. 2002. Purification, characterization, and identification of novel inhibitors of the β-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Antimicrob Agents Chemother 46: 1310-1318. http://dx.doi.org/10.1128/AAC.46.5.1310-1318.2002.
39. Khandekar SS, Gentry DR, Van Aller GS, Warren P, Xiang H, Silverman C, Doyle ML, Konstantinidis AK, Brandt M, Daines RA, Lonsdale JT. 2001. Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae β-ketoacyl-acyl carrier protein synthase III (FabH). J Biol Chem 276:30024-30030. http://dx.doi.org/10.1074/jbc .M101769200.
40. Kodali S, Galgoci A, Young K, Painter R, Silver LL, Herath KB, Singh SB, Cully D, Barrett JF, Schmatz D, Wang J. 2005. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem 280: 1669-1677. http://dx.doi.org/10.1074/jbc.M406848200.
41. Trajtenberg F, Altabe S, Larrieux N, Ficarra F, de Mendoza D, Buschiazzo A, Schujman GE. 2014. Structural insights into bacterial resistance to cerulenin. FEBS J 281: 2324-2338. http://dx.doi.org/10 .1111/febs.12785.
42. Beranova J, Mansilla MC, de Mendoza D, Elhottova D, Konopasek I. 2010. Differences in cold adaptation of Bacillus subtilis under anaerobic and aerobic conditions. J Bacteriol 192:4164-4171. http://dx.doi.org/10 .1128/JB.00384-10.
43. Qiu X, Choudhry AE, Janson CA, Grooms M, Daines RA, Lonsdale JT, Khandekar SS. 2005. Crystal structure and substrate specificity of the β-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Prot Sci 14:2087-2094. http://dx.doi.org/10.1110/ps.051501605.
44. Schujman GE, Paoletti L, Grossman AD, de Mendoza D. 2003. FapR, a bacterial transcription factor involved in global regulation of membrane lipid biosynthesis. Dev Cell 4:663-672. http://dx.doi.org/10.1016/S1534 -5807(03)00123-0.
45. Martinez MA, Zaballa ME, Schaeffer F, Bellinzoni M, Albanesi D, Schujman GE, Vila AJ, Alzari PM, de Mendoza D. 2010. A novel role of malonyl-ACP in lipid homeostasis. Biochemistry 49:3161-3167. http://dx .doi.org/10.1021/bi100136n.
46. Albanesi D, Reh G, Guerin ME, Schaeffer F, Debarbouille M, Buschiazzo A, Schujman GE, de Mendoza D, Alzari PM. 2013. Structural basis for feed-rorward transcriptional regulation of membrane lipid homeostasis in Staphylococcus aureus. PLoS Pathog 9:e1003108. http://dx.doi.org/10 .1371/journal.ppat.1003108.
47. Schujman GE, Altabe S, de Mendoza D. 2008. A malonyl-CoAdependent switch in the bacterial response to a dysfunction of lipid metabolism. Mol Microbiol 68:987-996. http://dx.doi.org/10.1111/j.1365 -2958.2008.06202.x.
48. Parsons JB, Frank MW, Jackson P, Subramanian C, Rock CO. 2014. Incorporation of extracellular fatty acids by a fatty acid kinase-dependent pathway in Staphylococcus aureus. Mol Microbiol 92:234-245. http://dx .doi.org/10.1111/mmi.12556.
49. Heath RJ, Rock CO. 1996. Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. J Biol Chem 271:1833-1836. http://dx.doi.org/10.1074/jbc.271.4.1833.
50. Parsons JB, Rock CO. 2013. Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res 52:249-276. http://dx.doi.org/10.1016/j .plipres.2013.02.002.
51. Kreiswirth BN, Lofdahl S, Betley MJ, O'Reilly M, Schlievert PM, Bergdoll MS, Novick RP. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305:709-712. http://dx.doi.org/10.1038/305709a0.
52. D'Elia MA, Pereira MP, Chung YS, Zhao W, Chau A, Kenney TJ, Sulavik MC, Black TA, Brown ED. 2006. Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J Bacteriol 188:4183-4189. http://dx.doi .org/10.1128/JB.00197-06.
53. Bose JL, Fey PD, Bayles KW. 2013. Genetic tools to enhance the study of gene function and regulation in Staphylococcus aureus. Appl Environ Microbiol 79:2218-2224. http://dx.doi.org/10.1128/AEM.00136-13.
54. Gajiwala KS, Margosiak S, Lu J, Cortez J, Su Y, Nie Z, Appelt K. 2009. Crystal structures of bacterial FabH suggest a molecular basis for the substrate specificity of the enzyme. FEBS Lett 583:2939-2946. http://dx.doi .org/10.1016/j.febslet.2009.08.001.